# Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With Tuberculosis

> **NCT03478033** · NA · UNKNOWN · sponsor: **Shanghai Public Health Clinical Center** · enrollment: 230 (estimated)

## Conditions studied

- Tuberculosis, Pulmonary
- AIDS

## Interventions

- **DRUG:** Rifampicin
- **DRUG:** Rifabutin

## Key facts

- **NCT ID:** NCT03478033
- **Lead sponsor:** Shanghai Public Health Clinical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04-15
- **Primary completion:** 2020-06-01
- **Final completion:** 2020-12-31
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2018-04-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03478033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03478033, "Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With Tuberculosis". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT03478033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*